person · Reporting owner

Forese Laura L

Disclosed activity across 2 companies

Tapewire entity: 40046
SEC CIK: 0001637195

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Surgery Partners, Inc.SGRY · Entity 4534	Director	June 05, 2026	June 09, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Surgery Partners, Inc.

Report date June 05, 2026 · Filed June 09, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	18,531	Reported balance After 2026-06-05 transaction · row 1 1 source row Row 1 · 2026-06-05 · Grant · Acquired 11,670 · Balance 18,531 F1: Shares will vest on June 5, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Shares will vest on June 5, 2027.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CANTEL MEDICAL CORP

Report date June 02, 2021 · Filed June 02, 2021

Section 16 reporting ended · disclosed 2021-06-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $.10 per shareSEC Table I · non-derivative	Direct	0	Reported balance After 2021-06-02 transaction · row 1 1 source row Row 1 · 2021-06-02 · Disposition to issuer · Disposed 7,570 · Balance 0 F1: Represents shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration").

F2: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 05, 2026 Filed Jun 9, 2026 20:28 UTC	Surgery Partners, Inc. SGRY · Entity 4534	GrantCommon Stock	11,670	$13.71	$159,995.70	Disclosure SEC source: 0001638833-26-000061 · wk-form4_1781036885.xml · nonDerivative · entry 1 Forese Laura L · CIK 0001637195 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,531 F1 · shares: Shares will vest on June 5, 2027. Read SEC document
June 10, 2025 Filed Jun 12, 2025 20:26 UTC	Surgery Partners, Inc. SGRY · Entity 4534	GrantCommon Stock	6,861	$23.32	$159,998.52	Disclosure SEC source: 0001638833-25-000112 · wk-form4_1749759958.xml · nonDerivative · entry 1 Forese Laura L · CIK 0001637195 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,861 F1 · shares: Shares will vest on June 10, 2026. Read SEC document
June 02, 2021 Filed Jun 2, 2021 17:25 UTC	CANTEL MEDICAL CORP CMD · Entity 138805	Disposition to issuerCommon Stock, par value $.10 per share	7,570	$80.59	$610,066.30	Disclosure SEC source: 0001104659-21-075852 · tm2118222-9_4seq1.xml · nonDerivative · entry 1 Forese Laura L · CIK 0001637195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Represents shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2 · kind: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59. F1 · shares: Represents shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2 · shares: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59. F1 · price: Represents shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2 · price: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59. Read SEC document
July 31, 2020 Filed Jul 31, 2020 18:06 UTC	CANTEL MEDICAL CORP CMD · Entity 138805	GrantCommon Stock	1,935	$0.00	$0.00	Disclosure SEC source: 0000019446-20-000048 · wf-form4_159623316183870.xml · nonDerivative · entry 1 Forese Laura L · CIK 0001637195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,570 Read SEC document
July 31, 2019 Filed Aug 2, 2019 15:21 UTC	CANTEL MEDICAL CORP CMD · Entity 138805	GrantCommon Stock	713	$0.00	$0.00	Disclosure SEC source: 0000019446-19-000045 · edgar.xml · nonDerivative · entry 1 Forese Laura L · CIK 0001637195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,635 Read SEC document
July 31, 2018 Filed Aug 2, 2018 16:59 UTC	CANTEL MEDICAL CORP CMD · Entity 138805	GrantCommon Stock	712	$0.00	$0.00	Disclosure SEC source: 0000019446-18-000035 · edgar.xml · nonDerivative · entry 1 Forese Laura L · CIK 0001637195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,922 Read SEC document
July 31, 2017 Filed Aug 1, 2017 14:52 UTC	CANTEL MEDICAL CORP CMD · Entity 138805	GrantCommon Stock	875	$0.00	$0.00	Disclosure SEC source: 0000019446-17-000026 · edgar.xml · nonDerivative · entry 1 Forese Laura L · CIK 0001637195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,210 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.